Abstract
The treatment of patients with metastatic colon cancer has evolved tremendously over the past 10 years, with improved overall survival (OS) rates as a result of the advent of several important agents. Following the results of important adjuvant trials, the incorporation of oxaliplatin into the adjuvant setting has significantly increased the disease-free survival and OS rates in patients who undergo curative resection. However, still a significant number of patients will present with recurrent disease after being treated with oxaliplatin-containing chemotherapy regimens. Herein, we present approaches to the chemotherapeutic management of such patients with a review of the literature.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 321-324 |
| Number of pages | 4 |
| Journal | Clinical Colorectal Cancer |
| Volume | 7 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 2008 |
| Externally published | Yes |
Keywords
- Metastasis
- Oxaliplatin
- Platinum resistance
- Recurrence
ASJC Scopus subject areas
- Oncology
- Gastroenterology